Delink drug prices from R&D costs: UN


Posted on:19 Sep 2016 09:24:12

Delink drug prices from R&D costs: UN
19 September 2016 Current Affairs: The United Nations High-Level Panel on Access to Medicines has called for delinking drug prices from research and development (R&D) costs. The report submitted by panel calls for human rights to be placed over intellectual property laws of pharmaceutical companies and incoherence between them should be narrowed.

All countries must freely be able to use flexibilities granted under TRIPS (Trade-Related Aspects of Intellectual Property Rights) to access affordable medicines. Countries that retaliate and threaten against generic drugs makers in different countries under the TRIPS Agreement must be forced to face significant sanctions. Public health assessments must be done with every free trade negotiation to assess the possible impact on public health and creation of public health patentability criteria. 

Governments engaged in bilateral and regional trade and investment treaties should ensure that these agreements do not include provisions that interfere with their obligations to fulfil the right to health. Research institutions and universities that receive public funding must prioritize public health objectives over financial returns in their patenting and licensing practices. Governments should increase their current levels of investments to in heath technology innovation to address unmet needs.


Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs June 2017

24 JUNE
NEWS
23 JUNE
NEWS
22 JUNE
NEWS
21 JUNE
NEWS

Current Affairs May 2017

31 MAY
NEWS
30 MAY
NEWS
29 MAY
NEWS
27 MAY
NEWS

Current Affairs April 2017

29 APRIL
NEWS
28 APRIL
NEWS
27 APRIL
NEWS
26 APRIL
NEWS